Influenza and ARVI: similarities and differences of the diseases

95%

ARVI and influenza are infectious viral respiratory pathologies accounting for up to 95% of infectious diseases.

200+

ARVI is caused by more than 200 types of viruses including the influenza virus being one of the most dangerous of them.1 The incidence of these diseases is registered globally all year round with the peak falling on the cold season.

Symptoms of influenza and ARVI

Symptoms of influenza and ARVI

Both of the diseases can be recognized by the first signs. The differences between ARVI and influenza consist in the fact that the acute respiratory viral infection does not cause severe complications.

The influenza pathogen is constantly changing. It's a serious disease, which can cause severe complications2 both in adults and children.

Difference between ARVI and influenza symptoms

Mode of infection

Mode of infection

  • ARVI

    Contact with an infected person or via household items; droplet spread.

  • INFLUENZA

    Droplet spread from an infected person as a result of close contact, conversation, sneezing or coughing.

Disease onset

Disease onset

  • ARVI

    Gradual augmentation of symptoms.

  • INFLUENZA

    Sudden and severe feeling unwell.

Elevated body temperature

Elevated body temperature

  • ARVI

    Up to 38–38,5 °C for up to 3 days.

  • INFLUENZA

    Higher than 39 °C with sudden increase for up to 5 days.

Runny nose

Runny nose

  • ARVI

    Often appears from the first days of infection, sneezing.

  • INFLUENZA

    Moderate nasal congestion manifests itself on day 2–3 . Sneezing is rare.

Sore throat

Sore throat

  • ARVI

    Redness and soreness are pronounced and frequent. Appear at once.

  • INFLUENZA

    Not always. Redness and soreness can appear on day 2–3 after the infection.

Cough

Cough

  • ARVI

    Productive or non-productive, from the first days of infection.

  • INFLUENZA

    Troublesome, accompanied by pain and cramping behind the breastbone.

Lymph node condition

Lymph node condition

  • ARVI

    Enlarged.

  • INFLUENZA

    Often not changed.

General well-being

General well-being

  • ARVI

    Drowsiness, severe fatigue. Occurs fast.

  • INFLUENZA

    Rapid loss of strength.

Additional symptoms

Additional symptoms

  • ARVI

    Headache, conjunctivitis, intestinal disorders are possible.

  • INFLUENZA

    Insomnia, migraine attacks, redness of the sclera of the eyes, noise and congestion in the ears.

Disease development

Disease development

  • ARVI

    Symptoms develop slowly.

  • INFLUENZA

    Symptoms appear at once, condition worsens rapidly.

Intoxication

Intoxication

  • ARVI

    Symptoms are mild.

  • INFLUENZA

    Symptoms augment rapidly and are expressed in chills, muscle, joint, head ache, photophobia, nausea, vomiting, and diarrhea.

Drag to view
Polyoxidonium pack
Polyoxidonium® helps combat viral infections, reduce inflammation and intoxication8 and improve the patient's condition from the first days of treatment.9
The principal difference between ARVI and influenza is occurrence of complications. ARVI is easier to treat, but in the absence of therapy it can provoke complications on the ENT-organs, ears, pneumonia and bronchitis.
vs
Influenza more often causes complications: the disease can lead to viral and bacterial inflammation of the lungs, tissue edema and damage to the membranes of the brain, kidneys, heart, joints and other organs.3

What is the danger of influenza and ARVI?

people icon
291 000 — 646 000
people4

A full-scale study conducted by the US Centers for Disease Control and Prevention and WHO has revealed that 291,000–646,000 people die annually of influenza and its complications worldwide4. The disease affects mostly children, elderly people and those suffering from chronic diseases.

If influenza and ARVI are not timely treated, the inflammatory process will spread beyond the respiratory tract, invading other organs.

Virus spread infographics

Surface of respiratory tract mucosa (nose, mouth)
Trachea
Bronchi
Deep layers of respiratory tract epithelium
Lungs
Virus spread
Virus spread

Most frequent influenza and ARVI complications5

BODY SYSTEM DISEASES OCCURRENCE RATE
Cardiovascular system Myocarditis, pericarditis Rare
Nervous system Meningitis, meningoencephalitis, encephalitis, neuralgia, polyradiculoneuritis, Guillain-Barré syndrome Rare, but severe
ENT-organs Otitis, sinusitis, laryngitis, tonsillitis, sinusitis, rhinopharyngitis Frequent
Respiratory organs Tracheitis, bronchitis, pneumonia, acute respiratory distress syndrome, obstructive syndrome Frequent
Kidneys Glomerulonephritis Rare, with severe consequences
pack Polyoxidonium
Polyoxidonium® helps prevent the development of bacterial complications and contributes to antibacterial resistance preventing the development of complications of a viral disease.14

Modes of transmission

The virus is active for 2 hours
active for the transmission
ARVI

The modes of transmission depend on the pathogen. In case with ARVI the virus is active for the transmission from one person to another for two hours! The entrance gate for acute respiratory viral infection is mucous membranes of the nose, mouth and eyes.

ARVI can be also transmitted via droplet spread or contact. An infected person touches a lot of objects within 2 hours, and other people can be infected at once by contacting the objects.

ARVI transmission modes

  • dishes
    Household items (dishes, towels, hairbrushes)
  • Transport
    Transport: handles, seats
  • chairs
    Indoors: door knobs, tables, chairs
  • Crowded places
    Crowded places
  • Toys
    Toys
  • Dirty hands
    Dirty hands (touching the face)
  • Personal belongings
    Personal belongings of the infected person
The virus is active for up to 21 days
for up to 21 days
INFLUENZA

The situation with the influenza virus is different, since it is transmitted mainly by droplet spread. However, the virus is also transmitted via contact and household items.

The influenza virus remains viable for up to 21 days. The source of infection is an infected person, and in some cases the virus can be transmitted from animals to humans6.

Influenza transmission modes

  • coughing
    Droplet spread via sneezing, coughing, emotional conversation. The virus is transmitted with saliva and phlegm containing pathogenic flora.
  • household items
    Via household items (bed sheets, dishes, toiletries, toys)
  Polyoxidonium
Polyoxidonium® can combat viruses by activating the synthesis of alpha and gamma interferons, alleviate disease severity12 and reduce the clinical manifestations of inflammation10.

Influenza and ARVI prevention tips

drinking water

The best protection against acute respiratory viral infections is your own immunity. Take care of the protective functions of your body in advance.

Polyoxidonium® can increase the body's resistance to viral infections8, boost immunity and reduce ARVI reoccurrence13.

Polyoxidonium® boosts immunity and reduces ARVI reoccurrence

Has immunomodulatory, detoxifying, anti-inflammatory, and antioxidant properties
Can improve the body's resistance to viral infections8 and alleviate influenza and ARVI severity12
Can reduce the risk of complications of viral diseases,10 including pneumonia11
Is compatible with many drug products, suitable for children and adults with allergic pathologies8
Can absorb toxins and remove them from the body, reducing intoxication8 and improving the patient's condition
In case of any drug-associated adverse events or any claims to the product quality, please contact NPO Petrovax Pharm, LLC:
Or use pharmacovigilance feedback page: http://petrovax.ru/medication/safety
  1. https://cyberleninka.ru/article/n/sovremennye-printsipy-diagnostiki-i-lecheniya-orv/upload/images/viewer
  2. http://cgon.rospotrebnadzor.ru/content/22/27/3120/
  3. https://eduherald.ru/ru/article/view?id=17378
  4. https://www.who.int/influenza/ru/
  5. https://mosgorzdrav.ru/ru-RU/news/default/card/3038.html
  6. https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Ostrye_respiratornye_virusnye_infekcii_i_gripp_etiologiya_diagnostika_i_algoritm_lecheniya/
  7. https://www.who.int/ru/news-room/fact-sheets/detail/influenza-(seasonal)
  1. Patient information leaflet for Polyoxidonium®.
  2. Vavilova, V.P., Vavilov, A.M., Cherkayeva, A.Kh. (2015). Possibilities of modern therapy for acute respiratory viral infections in children. Pediatrics (Appendix to Consilium Medicum), 3.
  3. Karaulov, A.V., Gorelov, A.V. (2019). The use of azoximer bromide for treatment of inflammatory infections of respiratory system in children: a meta-analysis of controlled clinical studies. Journal of Infectology, vol. 11, No. 4, 31–41.
  4. Mavzyutova, G.A., Mukhamadiyeva, L.R., Fazlyeva, R.M., Mirsayeva, G.Kh., Tyurina, E.B. (2015). Rational immunotherapy in the combination treatment of community-acquired pneumonia. Medical Council, 16.
  5. Garaschenko, T.I., Karneeva, O.V., Tarasova, G.D., et al. (2020). Influence of local application of Polyoxidonium on symptoms and course of acute respiratory viral infection in children: results of multicenter double-blind placebo-controlled study. Consilium Medicum, 22(3), 80–86.
  6. Kharit, S.M., Galustyan, A.N. (2017). Azoximer bromide is a safe and effective drug for treatment of acute upper respiratory tract infections in children: an overview of the results of double-blind, placebo-controlled, randomized clinical trials of phase II and III. Pediatrics (Appendix to Consilium Medicum), 2.
  7. Morozova, S.V. (2010). The use of Polyoxidonium immunocorrecting drug in acute infectious inflammatory pathology of ENT-organs. Russian Medical Journal, vol. 18, No. 24.
Asc a question
If you have a non-standard question, please contact us. Attention! Referring to the site is not a substitute for consulting a doctor.
* Requirements fields
Asc a question
The question has been successfully sent, we will contact you shortly
Attention!

The information posted in this section is intended for medical and / or pharmaceutical professionals. Please confirm that you are a professional in the respective field.